
US-based Precision Biosciences, Inc. is a biotech firm specializing in cancer treatment solutions.
Founded in Durham, United States, Precision BioSciences, Inc. is a biotech company with a core mission to develop innovative treatments for cancer and other hard-to-treat conditions. Their vision is to leverage their proprietary ARCUS genome editing technology to create a new class of medicines that can potentially cure rare genetic diseases. ARCUS uses sequence-specific DNA-cutting enzymes to precisely edit the DNA of living cells, enabling the insertion, removal, or repair of genetic material.
Notable affiliated people include the scientists who discovered and developed the ARCUS platform. Precision BioSciences has attracted significant investment from leading biotech investors and has achieved key milestones in advancing their genome editing technology. Their impact is evident in the promising preclinical and clinical results that demonstrate the potential of ARCUS to address unmet medical needs, positioning the company as a leader in the field of genome editing and therapeutic development.

Editas Medicine

Beam Therapeutics
beamtx.com

Cogent Biosciences
cogentbio.com

Caribou Biosciences
cariboubio.com

BridgeBio Pharma
bridgebio.com

Arcus Biosciences
arcusbio.com

AccuraGen

Personalis
personalis.com

Caris Life Sciences
carisls.com

Arbor Biotechnologies
arbor.bio

OncoPrecision
oncoprecision.bio

Acrigen Biosciences
acrigen.com

Whitehawk Therapeutics
aadibio.com

Blueprint Medicines

Encoded Therapeutics
Companies similar to Precision BioSciences include Editas Medicine, Beam Therapeutics, Cogent Biosciences and Caribou Biosciences.
Precision BioSciences was founded in 2006.
Precision BioSciences' headquarters is located in Durham, NC, US.
Precision BioSciences' most recent funding round was for $50M (USD) in June 2022.
As of Jun 21, 2022, Precision BioSciences has disclosed funding of $225.2M (USD). Undisclosed round amounts are excluded.
Precision BioSciences has 198 employees as of Feb 6, 2024.